Clinical Trials
9
Active:2
Completed:4
Trial Phases
3 Phases
Phase 1:7
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (77.8%)Phase 2
1 (11.1%)Phase 3
1 (11.1%)A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women
Phase 1
Active, not recruiting
- Conditions
- PostmenopausalHealthy Adult Female Participants
- Interventions
- Drug: LAE102 SCDrug: Placebo SCDrug: LAE102 IVDrug: Placebo IV
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-09-11
- Lead Sponsor
- Laekna Limited
- Target Recruit Count
- 32
- Registration Number
- NCT06908707
- Locations
- 🇺🇸
Fortrea Clinical Trials, Daytona Beach, Florida, United States
Evaluate LAE102 in Healthy and Overweight/Obese Subjects
Phase 1
Recruiting
- Conditions
- Overweight and Obese Volunteers
- Interventions
- Drug: LAE102 intravenous administrationDrug: placebo subcutaneous administrationDrug: placebo intravenous administrationDrug: LAE102 subcutaneous administrationDrug: LAE102 multiple subcutaneous administrationDrug: Placebo multiple subcutaneous administration
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Laekna Limited
- Target Recruit Count
- 124
- Registration Number
- NCT06493084
- Locations
- 🇨🇳
Fudan Zhongshan Hospital, Shanghai, Shanghai, China
Human Mass Balance and Biotransformation Study of [14C]Afuresertib
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: [14C]Afuresertib
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Laekna Limited
- Target Recruit Count
- 6
- Registration Number
- NCT05489744
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
PhI to Solid Tumors and PhII to Locally Advanced or mTNBC
Phase 1
Completed
- Conditions
- Solid TumorTNBC - Triple-Negative Breast Cancer
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Laekna Limited
- Target Recruit Count
- 21
- Registration Number
- NCT05390710
- Locations
- 🇨🇳
The first affiliated hopsital of bengbu medical college, Bengbu, Anhui, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Sun Yat-sen Memorial Hospital, Guangzhou, China
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Phase 1
Active, not recruiting
- Conditions
- Esophageal CancerGastric and Gastroesophageal Junction AdenocarcinomaSolid TumorNSCLCCervical CancerEndometrial Cancer
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Laekna Limited
- Target Recruit Count
- 167
- Registration Number
- NCT05383482
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chengdu, China
🇨🇳Jilin Cancer Hospital, Chang chun, Jilin, China
- Prev
- 1
- 2
- Next
News
No news found